Skip to main content
. 2024 Jun 20;32(7):1141–1162. doi: 10.32604/or.2024.050350

Table 2. Case studies on the use of various ALK inhibitors in individuals with advanced/metastatic IMT.

Reference Targeted therapy* ALK status Other treatment Response to treatment Patient information (age, sex, primary tumor site)
[189] Crizotinib 500 mg/day RANBP2-ALK rearrangement Surgery PR 22; male; pelvis with peritoneal dissemination
[190] Crizotinib ALK rearrangement CR 45; female; liver; metastatic
[191] Crizotinib 250 mg/2 times a day RANBP2-ALK rearrangement Surgery, chemotherapy with doxorubicin CR 22; male; pelvis
[192] Crizotinib CLTC-ALK rearrangement SD 24; male; omentum, liver, colon
[193] Crizotinib 250 mg on alternate days DCTN1-ALK rearrangement Pazopanib PR 50; female; uterine
[194] Crizotinib 200 mg/twice daily CR 7; female; right eye
[195] Crizotinib 250 mg/2 times a day EML4-ALK rearrangement Non-steroidal anti-inflammatory drugs, steroids, vinblastine, combination chemotherapy with alternate VAC/VA, and vinorelbine and methotrexate, palliative radiotherapy CR 16; female; right arm
[196] Crizotinib RANBP2-ALK rearrangement 6 cycles of chemotherapy in 4 was gemcitabine with docetaxel PR 15; female; ovary; recurrence
[82] Crizotinib 250 mg/2 times a day NUMA1-ALK rearrangement Nivolumab at 3 mg/kg intravenously every 2 weeks CR 21; female; left arm; metastatic
[106] Crizotinib 250 mg/2 times a day LRRFIP1-ALK rearrangement PR 15; male; hip
[197] Crizotinib 500 mg daily ALK rearrangement Surgery CR 37; female; right adrenal gland
and inferior vena cava; metastatic
[198] Crizotinib ALK wt PR 31; male; lung; metastatic
[199] Crizotinib 250 mg/2 times a day IGFBP5-ALK-Rearrangement Surgery CR 56; female; uterus; recurrence
[200] Crizotinib 280 mg/m2/day CLTC-ALK rearrangement CR 8-months; male; common bile duct and celiac artery
[201] Alectinib 600 mg/day SQSTM1-ALK rearrangement Surgery PR 31; female; Recurrence of multifocal, unresectable multifocal disease
[202] Ceritinib 300 mg/m2/day ALK rearrangement Surgery, nonsteroidal anti-inflammatory drugs, chemotherapy with methotrexate and vinorelbine CR 17 years old; male; relapse with lung metastasis
[203] Alectinib TNS1-ALK rearrangement Surgery, 6 cycles of olaratumab (a PDGFR-alpha blocker) and doxorubicin CR 71; female; uterus; recurrence
[31] Alectinib 600 mg/day SQSTM1-ALK rearrangement PR 46; male; unresectable recurrence
[204] Ensartinib 225 mg/day RANBP2-ALK rearrangement PR 31male; metastatic recurrence
[205] Alectinib 600 mg/day EML4-ALK rearrangement PR 26; male; left forearm; metastatic
[206] Alectinib 600 mg/day EML4-ALK rearrangement Surgery PR 55; male; metastatic
[207] Crizotinib Ceritinib to 600 mg daily TPM3-ALK rearrangement Surgery, celecoxib PR 32; male; left lung and chest wall, medial right thigh, right gluteal muscle, and omentum
[208] Crizotinib Ceritinib 750 mg/daily ALK G1269A mutation Surgery PR 36; female; lung; recurrence
[209] Crizotinib Ceritinib 750 mg/daily Alectinib 600 mg/daily Lorlatinib 100 mg/daily ALK rearrangement PR 18; female; brain; metastatic
[210] Crizotinib Brigatinib 180 mg/daily Lorlatinib 180 mg/daily Rearrangement of the TFG-ROS1 rearrangement Surgery CR 14; female; brain; metastatic
[211] Crizotinib 250 mg/twice daily Alectinib 600 mg/twice daily Ceritinib 450 mg/daily Lorlatinib 100 mg/daily PRRC2B-ALK rearrangement Surgery PR 42; female; pelvis; recurrence
[212] Crizotinib 250 mg/twice daily Ceritinib 450 mg/daily Alectinib 600 mg/twice daily RRBP1-ALK rearrangement PR 22; male; abdomen; metastatic

Note: *In the studies referenced, the doses administered exhibited variability throughout the therapeutic course, mainly due to drug-related toxicities. We presented the initial or principal dose used among the patient cohort. CR-complete response, PR-partial response, SD-stable disease, ALK-anaplastic lymphoma kinase, RANBP2-ran binding protein 2, CLTC-clathrin heavy chain, RRBP1-ribosome-binding protein 1, PRRC2B-proline-rich coiled-coil 2B, DCTN1-dynactin subunit 1, EML4-echinoderm microtubule-associated protein-like 4, NUMA1-nuclear mitotic apparatus protein 1, LRRFIP1-leucine-rich repeat of flightless-1 interacting protein 1, IGFBP5-insulin-like growth factor-binding protein 5, SQSTM1-sequestosome 1, TNS1-tensin 1, TPM3-tropomyosin 3 TFG-tropomyosin-receptor kinase fused gene, ROS1-proto-oncogene 1 receptor tyrosine kinase, PDGFR-platelet-derived growth factor receptor, VAC/VA-vincristine, actinomycin-D, and cyclophosphamide.